HDAC9 and cancer: Taken together, a deeper insight into HDAC/P65 inhibition and systemic monocyte reprogramming in cancer may contribute to novel therapeutic interventions that have the potential to set long-lasting anticancer immunity and halt cancer progression (Figure 1).